Diabetes not only affects glucose metabolism but also disrupts fat and protein metabolism. Over time, these metabolic disruptions can lead to complications such as cardiovascular disease, nerve damage, kidney disease, and more. Given the established role of type 2 diabetes and other metabolic conditions — such as obesity, dyslipidemia, and metabolic syndrome — as recognized risk factors for cardiovascular diseases, VIVIT’s patient cohorts include a significant number of patients with these metabolic disorders. This composition allows for a specialized focus in our research on these adverse metabolic conditions. Our metabolic research explores the complex interplay of genetic, environmental, and lifestyle factors driving these disorders, while also evaluating their impact on the prognosis and outcomes of patients at cardiovascular risk. In addition to this patient-driven research, VIVIT engages in basic research of obesity-related adverse conditions. For this purpose, adipocytes are cultured in VIVIT’s laboratory under different conditions, for instance, in a low-oxygen environment, to mimic the effects of oxygen deprivation on adipose tissue. This state of chronic hypoxia is known to trigger inflammatory reactions and metabolic changes, uncovering mechanisms underlying obesity-related diseases.

Through these approaches, VIVIT aims to advance the understanding of the mechanisms linking metabolic disorders like diabetes and obesity to cardiovascular diseases. By identifying key pathways and critical biomarkers, our research significantly contributes to the growing body of knowledge in metabolic and cardiovascular science and helps to develop innovative strategies for prevention, early detection, and personalized treatments.